Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function

Hepatic Carcinoma Clinical Trial

Official title:

Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02352935
• Other study ID #: JF-20150127(5)
• Status: Completed
• Phase: N/A
• Start date: January 1, 2015
• Est. completion date: January 1, 2021

Study information

• Verified date: April 2019
• Source: Fuda Cancer Hospital, Guangzhou
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be recorded.

Description:

Hepatic carcinoma is the fifth most common cancer worldwide and a large proportion of patients are unsuitable for tumor resection because of factors such as poor hepatic reserve(cirrhosis) which directly lead a poor liver function. Direct ablative treatments include radiofrequency ablation, microwave (MW) ablation and cryotherapy and irreversible electroporation had been used successful as a therapeutic choice for unresectable patients. At the same time，Irreversible electroporation(IRE)，which was applied with a novel ablation technology, can induce tissue necross by utilizing short pulses of high-voltage electrical energy. The technique also had many advantages, including Short ablation time, preservation of vital structures within IRE-ablated zone, avoidance of heat/cold-sink effect, complete ablation with well-demarcated margin and real-time monitoring of IRE ablation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 1, 2021
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Hepatic carcinoma diagnosed by positive biopsy or non-invasive criteria,

• not suitable for surgical resection or transplantation,

• have at least one, but less than or equal to 3 tumors,

• of the tumour(s) identified, each tumor must be = 5 cm in diameter,

• Child-Pugh class B or =12,

• Eastern Cooperative Oncology Group (ECOG) score of 0-1,

• American Society of Anaesthesiologists (ASA) score = 3,

• a prothrombin time ratio > 50%,

• platelet count > 80x109/L,

• ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,

• are able to comprehend and willing to sign the written informed consent form (ICF),

• have a life expectancy of at least 3 months.

Exclusion Criteria:

• eligible for surgical treatment or transplantation for HCC,

• Hepatic carcinoma developed on an already transplanted liver,

• cardiac insufficiency, ongoing coronary artery disease or arrhythmia,

• any active implanted device (eg Pacemaker),

• women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,

• have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System, are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatic Carcinoma

Intervention

Device:
• NanoKnife LEDC System
90 pulses of 70 microseconds each in duration will be administered per electrode pair

Locations

Country	Name	City	State
China	FUDA Cancer Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Fuda Cancer Hospital, Guangzhou

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Progress Free Survival (PFS)		2 years post treatment
Other	Over Survival (OS)		5 years post treatment
Primary	Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.		1 day post treatment to 14 days post treatment
Secondary	Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.		30 days (+/- 3 days) post treatment